Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
10.09
+0.01 (0.10%)
At close: Aug 14, 2026, 4:00 PM EDT
10.29
+0.20 (1.98%)
After-hours: Aug 14, 2026, 7:59 PM EDT
CRBP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
36
Market Cap
195.15M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 881.71K | -3.06M | -77.61% |
| Dec 31, 2020 | 3.94M | -32.21M | -89.11% |
| Dec 31, 2019 | 36.14M | 31.32M | 649.51% |
| Dec 31, 2018 | 4.82M | 2.38M | 97.62% |
| Dec 31, 2017 | 2.44M | 528.77K | 27.66% |
| Dec 31, 2016 | 1.91M | 1.26M | 194.80% |
| Dec 31, 2015 | 648.38K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 50.94M |
| Precision BioSciences | 45.06M |
| Voyager Therapeutics | 34.46M |
| Alpha Cognition | 15.26M |
| Keros Therapeutics | 15.01M |
| Pyxis Oncology | 11.04M |
| Innate Pharma | 10.57M |
| Korro Bio | 2.38M |
CRBP News
- 9 days ago - Corbus Pharmaceuticals price target lowered to $48 from $52 at Oppenheimer - TheFly
- 10 days ago - Corbus Pharmaceuticals Holdings Earnings release: Q2 2026 - Filings
- 10 days ago - Corbus Pharmaceuticals Holdings Quarterly report: Q2 2026 - Filings
- 11 days ago - Corbus reports last patient completes last visit in CANYON-1 trial - TheFly
- 11 days ago - Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity - GlobeNewsWire
- 18 days ago - Corbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial - TheFly
- 19 days ago - Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer - GlobeNewsWire
- 5 weeks ago - Corbus Pharmaceuticals appoints Viana Nicacio as chief medical officer - TheFly